Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Escalating Dose Intravenous Methotrexate Without Leucovorin Rescue vs. Oral Methotrexate and Single vs. Double Delayed Intensification for Children with Standard Risk Acute Lymphoblastic Leukemia - A Phase III Study Limited to Former CCG Institutions - CCG-1991

Next Previous
X
Search
Trial Profile

Escalating Dose Intravenous Methotrexate Without Leucovorin Rescue vs. Oral Methotrexate and Single vs. Double Delayed Intensification for Children with Standard Risk Acute Lymphoblastic Leukemia - A Phase III Study Limited to Former CCG Institutions - CCG-1991

Status: Completed
Phase of Trial: Phase III

Latest Information Update: 18 Sep 2021

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Antineoplastics; Cyclophosphamide; Cytarabine; Cytarabine; Daunorubicin; Dexamethasone; Doxorubicin; Mercaptopurine; Methotrexate; Methotrexate; Pegaspargase; Tioguanine; Vincristine
  • Indications Precursor cell lymphoblastic leukaemia-lymphoma
  • Focus Therapeutic Use

    • Most Recent Events

    • 23 Feb 2016 Biomarkers information updated
    • 18 Oct 2013 Event free survival tagged as primary as per CT.gov.
    • 12 Sep 2013 Planned End Date changed from 1 Jun 2000 to 1 Nov 2007.
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top